METHODS AND DEVICES FOR THE TREATMENT OF OCULAR DISEASES IN HUMAN SUBJECTS

• US 20150258120A1
• Filed: 11/08/2013
• Published: 09/17/2015
• Est. Priority Date: 11/08/2012
• Status: Abandoned Application

• Current Assignee: Clearside Biomedical, Inc.
• Original Assignee: Clearside Biomedical, Inc.
• Inventors: Zarnitsyn, Vladimir, Patel, Samirkumar, White, Daniel, Noronha, Glenn, Burke, Brian
• Application Number:
  US14/441,151
• Publication Number:
  US 20150258120A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/54 characterised by the route of administration
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/4439 containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole nicotine A61K31/465
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/12 Carboxylic acids; Salts or anhydrides thereof
• CPC Class Codes: A61K 47/26 Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• CPC Class Codes: A61K 47/38 Cellulose; Derivatives thereof
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61K 9/10 Dispersions; Emulsions A61K9/06 takes precedence; composition of dispersions, emulsions A61K47/00
• CPC Class Codes: A61K 9/16 Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51
• CPC Class Codes: A61M 2037/0023 Drug applicators using microneedles
• CPC Class Codes: A61M 2037/0061 Methods for using microneedles
• CPC Class Codes: A61M 37/0015 by using microneedles
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 27/10 for accommodation disorders, e.g. myopia
• CPC Class Codes: A61P 29/00 : Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 : for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/20 : for DNA viruses
• CPC Class Codes: A61P 37/02 : Immunomodulators
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/02 : Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07K 16/22 : against growth factors ; against growth regulators

Abstract

Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.

Claims

1-241. -241. (canceled)

242. A method of treating uveitis in a human subject in need thereof, the method comprising,

non-surgically administering an effective amount of a drug formulation comprising an anti-inflammatory drug to the suprachoroidal space (SCS) of the eye of the human subject in need of treatment of the posterior ocular disorder,

wherein upon administration, the drug formulation flows away from the insertion site and is substantially localized to the posterior segment of the eye.

243. The method of claim 242, wherein the uveitis is acute posterior uveitis.

244. The method of claim 242, wherein the anti-inflammatory drug is a steroid.

245. The method of claim 242, wherein the anti-inflammatory drug is mycophenolate, infliximab, nepafenac, azathioprine, cyclosphosphamide, dexamethasone, difluprednate, fluocinolone, fluorometholone, leteprednol, prednisolone acetate, prednisolone sodium phosphate, rimexolone, triamcinolone, bromfenac, diclofenac, fluibiprofen, ketorolac, adalimumab, etanercept, certolizumab, gotimumab, daclizumab, rituximab, abatacept, basiliximab, belimumab, anakinra, efalizuma, alefacept or natalizumab.

246. The method of claim 242, wherein the anti-inflammatory drug is triamcinolone.

247. The method of claim 242, wherein the effective amount of the drug sufficient to elicit a therapeutic response when administered to the SCS is less than the effective amount of the drug sufficient to elicit a therapeutic response when administered intravitreally, intracamerally, topically, parenterally or orally.

248. The method of claim 242, wherein the retention of the anti-inflammatory drug in the posterior segment of the eye is greater than the retention of the anti-inflammatory drug in the posterior segment of the eye when the anti-inflammatory drug is administered intravitreally, intracamerally, topically, parenterally or orally.

249. The method of claim 242, wherein an intraocular C_max of the drug is greater than an intraocular C_max of the drug, when the drug is administered intravitreally, intracamerally, topically, parenterally or orally.

250. The method of claim 242, wherein the systemic exposure of the drug is less than the systemic exposure of the drug when the drug is administered intravitreally, intracamerally, topically, parenterally or orally.

251. The method of claim 242, wherein the non-surgically administering includes conveying the effective amount of the drug formulation to the SCS via a microneedle having a length of from about 500 μ

m to about 1500 μ

m.

252. The method of claim 242, wherein the drug formulation comprises a suspension of microparticles or nanoparticles.

253. The method of claim 242, wherein the anti-inflammatory drug is triamcinolone acetonide.

254. The method of claim 242, wherein the intraocular pressure of the eye of the subject varies by no more than about 10% during the administration of the drug formulation.

255. The method of claim 247, wherein a dosage of the drug sufficient to elicit a therapeutic response when administered to the SCS is 50% or less of a dosage of the drug sufficient to elicit a therapeutic response when administered intravitreally, intracamerally, topically, parenterally or orally.

256. The method of claim 252, wherein the microparticles have a D₅₀ of 2 μ

m or less.

257. A composition comprising triamcinolone acetonide, carboxymethylcellulose sodium and polysorbate 80.

258. The composition of claim 257, wherein triamcinolone is in particulate and the particles have a D₅₀ of about 2 μ

m.

259. The composition of claim 257, wherein the microprticles have a D₉₉ of less than 10 μ

m.

260. The composition of claim 257, wherein the triancinolone acetonide is present in the composition at 40 mg/mL.

261. The composition of claim 257, further comprising sodium acetate.